<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012478</article-id><article-id pub-id-type="publisher-id">ACM-39449</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_56029734.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  术前PNI与IB1~IIA2期宫颈癌临床病理特征及PLNM的意义
  Significance of Preoperative PNI in Clinicopathological Characteristics and PLNM of Stage IB1~IIA2 Cervical Cancer
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>季</surname><given-names>雪超</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>爱平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>畅</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>卢</surname><given-names>彩霞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>赵</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学医学部，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学附属医院妇产科，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3194</fpage><lpage>3200</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：评估术前预后营养指数(prognostic nutritional index, PNI)与IB1~IIA2期宫颈癌(cervical cancer)临床病理特征的关系，以及评估盆腔淋巴结转移(pelvic lymphnode metastasis, PLNM)的意义。方法：采集2018年12月~2020年6月于青岛大学附属医院接受初始治疗方式为根治性子宫切除术及盆腔淋巴结切除术的101例IB1~IIA2期宫颈癌患者的检验结果及病理报告。采用受试者工作特征(ROC)曲线分析PNI预测IB1~IIA2期宫颈癌盆腔淋巴结转移的最佳临界值。统计学比较PLNM阴性和阳性组患者的临床病理特征，采用单因素、多因素logistic分析可能影响IB1~IIA2期宫颈癌PLNM的因素。结果：101例IB1~IIA2期宫颈癌中，PLNM阳性和阴性患者分别为31例和70例。依据ROC曲线，PNI预测IB1~IIA2期宫颈癌PLNM的最佳临界值为52.2，其中PNI ≤ 52.2者44例，PNI &gt; 52.2者57例。单因素、多因素logistic回归分析均证明，PNI是预测IB1~IIA2期宫颈癌PLNM的指标(P &lt; 0.05)。结论：术前外周血PNI是IB1~IIA2期PLNM的独立预测指标。
    Objective: To evaluate the significance of preoperative prognostic nutritional index (PNI) with clinicopathological features and pelvic lymphnode metastasis (PLNM) in stage IB1~IIA2 cervical cancer. Methods: From December 2018 to June 2020, 101 patients with stage IB1~IIA2 cervical cancer who underwent radical surgery in the Affiliated Hospital of Qingdao University were collected. Receiver operating characteristic (ROC) curve was used to analyze the optimal cut-off value of PNI in predicting PLNM of stage IB1~IIA2 cervical cancer. The clinicopathological characteristics of patients with PLNM negative and positive groups were compared statistically. Univariate and multivariate logistic analysis was used to analyze the factors that may affect PLNM in stage IB1~IIA2 cervical cancer. Results: In 101 cases of IB1~IIA2 cervical cancer, 31 cases were PLNM positive and 70 cases were negative. According to the ROC curve, the best cut-off value of PNI in predicting PLNM of stage IB1~IIA2 cervical cancer was 52.2, of which 44 cases were PNI ≤ 52.2, and 57 cases were PNI &gt; 52.2. Univariate and multivariate logistic regression analysis showed that PNI was a predictor of PLNM in stage IB1~IIA2 cervical cancer (P &lt; 0.10). Conclusion: Preoperative peripheral blood PNI is an independent predictor of PLNM in stage IB1~IIA2 cervical cancer. 
  
 
</p></abstract><kwd-group><kwd>宫颈癌，预后营养指数，淋巴结转移, Cervical Cancer</kwd><kwd> Prognostic Nutritional Index (PNI)</kwd><kwd> Lymphnode Metastasis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：评估术前预后营养指数(prognostic nutritional index, PNI)与IB1~IIA2期宫颈癌(cervical cancer)临床病理特征的关系，以及评估盆腔淋巴结转移(pelvic lymphnode metastasis, PLNM)的意义。方法：采集2018年12月~2020年6月于青岛大学附属医院接受初始治疗方式为根治性子宫切除术及盆腔淋巴结切除术的101例IB1~IIA2期宫颈癌患者的检验结果及病理报告。采用受试者工作特征(ROC)曲线分析PNI预测IB1~IIA2期宫颈癌盆腔淋巴结转移的最佳临界值。统计学比较PLNM阴性和阳性组患者的临床病理特征，采用单因素、多因素logistic分析可能影响IB1~IIA2期宫颈癌PLNM的因素。结果：101例IB1~IIA2期宫颈癌中，PLNM阳性和阴性患者分别为31例和70例。依据ROC曲线，PNI预测IB1~IIA2期宫颈癌PLNM的最佳临界值为52.2，其中PNI ≤ 52.2者44例，PNI &gt; 52.2者57例。单因素、多因素logistic回归分析均证明，PNI是预测IB1~IIA2期宫颈癌PLNM的指标(P &lt; 0.05)。结论：术前外周血PNI是IB1~IIA2期PLNM的独立预测指标。</p></sec><sec id="s2"><title>关键词</title><p>宫颈癌，预后营养指数，淋巴结转移</p></sec><sec id="s3"><title>Significance of Preoperative PNI in Clinicopathological Characteristics and PLNM of Stage IB1~IIA2 Cervical Cancer</title><p>Xuechao Ji<sup>1</sup>, Aiping Chen<sup>2</sup>, Chang Wang<sup>2</sup>, Caixia Lu<sup>2</sup>, Fei Zhao<sup>1</sup></p><p><sup>1</sup>Medical College of Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Department of Gynecology and Obstetrics, Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/48-1571713x4_hanspub.png" /></p><p>Received: Nov. 21<sup>st</sup>, 2020; accepted: Dec. 21<sup>st</sup>, 2020; published: Dec. 28<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/48-1571713x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To evaluate the significance of preoperative prognostic nutritional index (PNI) with clinicopathological features and pelvic lymphnode metastasis (PLNM) in stage IB1~IIA2 cervical cancer. Methods: From December 2018 to June 2020, 101 patients with stage IB1~IIA2 cervical cancer who underwent radical surgery in the Affiliated Hospital of Qingdao University were collected. Receiver operating characteristic (ROC) curve was used to analyze the optimal cut-off value of PNI in predicting PLNM of stage IB1~IIA2 cervical cancer. The clinicopathological characteristics of patients with PLNM negative and positive groups were compared statistically. Univariate and multivariate logistic analysis was used to analyze the factors that may affect PLNM in stage IB1~IIA2 cervical cancer. Results: In 101 cases of IB1~IIA2 cervical cancer, 31 cases were PLNM positive and 70 cases were negative. According to the ROC curve, the best cut-off value of PNI in predicting PLNM of stage IB1~IIA2 cervical cancer was 52.2, of which 44 cases were PNI ≤ 52.2, and 57 cases were PNI &gt; 52.2. Univariate and multivariate logistic regression analysis showed that PNI was a predictor of PLNM in stage IB1~IIA2 cervical cancer (P &lt; 0.10). Conclusion: Preoperative peripheral blood PNI is an independent predictor of PLNM in stage IB1~IIA2 cervical cancer.</p><p>Keywords:Cervical Cancer, Prognostic Nutritional Index (PNI), Lymphnode Metastasis</p><disp-formula id="hanspub.39449-formula50"><graphic xlink:href="//html.hanspub.org/file/48-1571713x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/48-1571713x7_hanspub.png" /> <img src="//html.hanspub.org/file/48-1571713x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>在全球女性发病率与死亡率的统计学分析中，宫颈癌居于第四位。其中仅2018年，全世界新增宫颈癌患者57.0万例，占所有女性癌症发病的6.6%；死亡患者31.1万例，占所有女性死亡的7.5% [<xref ref-type="bibr" rid="hanspub.39449-ref1">1</xref>]。宫颈癌标化发病率为13.1/10万，女性0~74岁累积发病风险为1.36%。在中国，每年新增宫颈癌病例约14万，死亡约3.7万 [<xref ref-type="bibr" rid="hanspub.39449-ref2">2</xref>]。有研究证实，盆腔淋巴结转移是提示宫颈癌复发和不良预后的关键指标，有淋巴结转移的患者术后均需补充放疗或化疗 [<xref ref-type="bibr" rid="hanspub.39449-ref3">3</xref>]。其中，对于IA1期宫颈癌，如无淋巴脉管间隙浸润，该期淋巴结转移率低于1%，不需要切除淋巴结。IA1期伴淋巴脉管间隙浸润和IA2期，可选择行宫颈锥切术及盆腔淋巴结切除术，或直接行根治性子宫颈切除术及盆腔淋巴洁切除术 [<xref ref-type="bibr" rid="hanspub.39449-ref3">3</xref>]。IB1~IIA2期宫颈癌患者的宫颈癌手术方式可选择行根治性子宫切除术 + 盆腔淋巴结切除术 &#177; 主动脉旁淋巴结切除术等 [<xref ref-type="bibr" rid="hanspub.39449-ref4">4</xref>]，但该手术可能导致患者出现多种并发症，如尿路感染、尿潴留、盆腔淋巴结囊肿、淋巴瘘、输尿管膀胱瘘、膀胱阴道瘘、肾积水、下肢淋巴水肿、神经损伤、腹膜炎、盆腔脓肿、肺栓塞、下肢静脉血栓 [<xref ref-type="bibr" rid="hanspub.39449-ref5">5</xref>] 等，严重影响宫颈癌患者的生活质量和心理健康。宫颈癌分期(FIGO 2018)中将有影像学或病理学依据的盆腔淋巴结转移归为IIIC期，同期放化疗为其首选治疗方式，因此宫颈癌患者如果影像学诊断有淋巴结转移，应建议患者行同期放化疗，以期尽量避免手术和放化疗多重治疗造成的损伤 [<xref ref-type="bibr" rid="hanspub.39449-ref6">6</xref>]。因此，在IB1~IIA2期宫颈癌治疗方案的选择上，鉴别宫颈癌患者有无淋巴结转移非常重要。所以，对于术前影像学检查阴性的宫颈癌患者，选择合适的指标以便准确评估盆腔淋巴结转移情况，对于改变患者的临床分期及选择合适的治疗方式至关重要。</p><p>肿瘤细胞的发生、侵袭与机体的营养与免疫状态密切相关，在选择治疗方案以及评估患者预后方面均具有重要的临床意义 [<xref ref-type="bibr" rid="hanspub.39449-ref7">7</xref>]。PNI代表了机体的营养与免疫状态。近些年来，许多研究表明，PNI对于评估癌症患者的生活质量及生存期具有重要的临床意义，而且在肺癌、食管癌、胃癌、结直肠癌 [<xref ref-type="bibr" rid="hanspub.39449-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.39449-ref9">9</xref>] 等恶性肿瘤中，PNI的预后评估价值已经得到临床研究证明，但与IB1~IIA2期宫颈癌PLNM的关系报道较少。目前，PLNM诊断的金标准仍是术后组织病理学检查，而CT、MRI、PET-CT等影像检查费用相对较高，且假阳性率及假阴性率较高，术前缺乏评估宫颈癌患者PLNM的指标。PNI由淋巴细胞计数总值 &#215; 5 +血清白蛋白之和 [<xref ref-type="bibr" rid="hanspub.39449-ref10">10</xref>] 计算得来，淋巴细胞、血清白蛋白均为宫颈癌患者术前的常规检查项目，检查费用相对较低，且计算较为简便。本文旨在评估PNI与宫颈癌临床病理特征的关系，以及其预测IB1~IIA2期宫颈癌PLNM的价值，为制定宫颈癌患者的治疗方案及评估预后提供参考依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 资料来源</title><p>收集2018年12月~2020年6月于青岛大学附属医院首选根治性子宫切除术及盆腔淋巴结切除术的IB1~IIA2期宫颈癌患者的检验结果及病理报告。纳入标准：患者术前FIGO (2018)分期IB1~IIA2；行根治性子宫切除术及盆腔淋巴结切除术；术前宫颈活检明确诊断为宫颈恶性肿瘤，术后组织病理学再次证实为宫颈恶性肿瘤；术前完善血常规、肿瘤细胞标记物、生化、CT等检查。排除标准：术前影像学提示淋巴结转移者；术前盆腔淋巴结穿刺活检病理提示淋巴结转移者；术前已行放疗、化疗或免疫治疗等辅助治疗者；合并有其他器官恶性肿瘤者；合并血液系统疾病或免疫系统疾病者；合并肝炎、肝硬化等疾病者。</p></sec><sec id="s6_2"><title>2.2. 临床资料收集</title><p>采集患者的年龄、术前FIGO分期、组织学分级、组织病理学类型、PLNM、脉管癌栓、宫旁浸润、间质浸润深度、肿瘤直径、阴道切缘等临床资料，术前SCCA值、淋巴细胞计数、白蛋白值，并由淋巴细胞 * 5 + 白蛋白之和计算得到PNI。</p></sec><sec id="s6_3"><title>2.3. 统计学处理</title><p>使用SPSS26.0软件。绘制PNI预测IB1~IIA2期宫颈癌PLNM的ROC曲线，并确定其最佳临界值、特异度和灵敏度；对PLNM阳性和阴性两组IB1~IIA2期宫颈癌患者，采用χ<sup>2</sup>检验比较临床病理特征；采用logistic回归分析影响IB1~IIA2期宫颈癌PLNM的独立因素。以双侧检验为准，P &lt; 0.10为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患者的基本资料</title><p>101例宫颈癌患者的中位年龄50岁(32~68岁)，中位体重指数(body mass index, BMI) 24.81 kg/m<sup>2</sup> (16.57~34.77 kg/m<sup>2</sup>)。FIGO分期：IB期者有53例(52.5%)，IIA期者有48例(47.5%)；组织病理学类型：鳞癌78例(77.2%)，腺癌21例(20.8%)，腺鳞癌1例(1%)，神经内分泌癌1例(1%)；组织学分级：G1者9例(8.9%)，G2者47例(46.5%)，G3者45例(44.6%)；脉管癌栓：阳性44例(43.6%)，阴性57例(56.4%)；间质浸润深度 &gt; 1/2者55例(54.5%)，≤ 1/2者46例(45.5%)；腹主动脉旁淋巴结转移阳性31例(30.7%)，阴性70例(69.3%)。中位肿瘤直径3.1 cm (0.1~8.8 cm)，中位SCCA 3.57 ng/ml (0.37~100.00 ng/ml)，中位淋巴细胞计数1.79 &#215; 10<sup>9</sup> [(0.70~3.48) &#215; 10<sup>9</sup>]，白蛋白值43.4 g/l (31.1~52.2 g/l)。</p></sec><sec id="s7_2"><title>3.2. PNI预测IB1~IIA2期宫颈癌PLNM的ROC曲线分析</title><p>根据最大约登指数原理，PNI预测IB1~IIA2期宫颈癌PLNM的最佳临界值为52.2。ROC曲线下面积(AUC)为0.752 (95% CI: 0.653~0.851, P &lt; 0.05)，敏感性为69.4%，特异性为74.4%。如图1。PNI &gt; 52.2者57例(56.4%)，PNI ≤ 52.2者44例(43.6%)。如图1。</p><p>图1. PNI预测IB1~IIA2期宫颈癌PLNM的ROC曲线</p></sec><sec id="s7_3"><title>3.3. PLNM 阳性和阴性组患者的临床病理学特征比较</title><p>PLNM阳性组与阴性组在FIGO分期、脉管癌栓、间质浸润深度、PNI等方面的临床病理学特征差异有统计学意义(P &lt; 0.10)，但在年龄、组织学分级、组织病理类型、宫旁浸润、肿瘤直径、阴道切缘及SCCA等方面无显著性差异(P &lt; 0.10)，见表1。</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of clinicopathological features between PLNM positive and negative patient</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >变量</th><th align="center" valign="middle" ></th><th align="center" valign="middle" >n</th><th align="center" valign="middle" >PLNM (+) (n = 31)</th><th align="center" valign="middle" >PLNM (−) (n = 70)</th><th align="center" valign="middle" >t或χ<sup>2</sup></th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >49.26 &#177; 8.48</td><td align="center" valign="middle" >50.67 &#177; 8.63</td><td align="center" valign="middle" >0.763</td><td align="center" valign="middle" >0.679</td></tr><tr><td align="center" valign="middle" >FIGO分期</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5.178</td><td align="center" valign="middle" >0.023</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >IB1~IB3</td><td align="center" valign="middle" >53</td><td align="center" valign="middle" >11</td><td align="center" valign="middle" >42</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >IIA1~IIA2</td><td align="center" valign="middle" >48</td><td align="center" valign="middle" >20</td><td align="center" valign="middle" >28</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >组织学分级</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.333</td><td align="center" valign="middle" >0.564</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >G1</th><th align="center" valign="middle" >9</th><th align="center" valign="middle" >2</th><th align="center" valign="middle" >7</th><th align="center" valign="middle" ></th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >G2/G3</td><td align="center" valign="middle" >102</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >63</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >组织病理学类型</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.122</td><td align="center" valign="middle" >0.289</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >鳞癌</td><td align="center" valign="middle" >23</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >非鳞癌</td><td align="center" valign="middle" >78</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >脉管癌栓</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >29.556</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >44</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >57</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >52</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >宫旁浸润</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.717</td><td align="center" valign="middle" >0.397</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >86</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >间质浸润深度</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >15.605</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >&gt;1/2</td><td align="center" valign="middle" >31</td><td align="center" valign="middle" >26</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >≤1/2</td><td align="center" valign="middle" >46</td><td align="center" valign="middle" >5</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >肿瘤大小(cm)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.443</td><td align="center" valign="middle" >0.23</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >&lt;4</td><td align="center" valign="middle" >61</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >45</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >≥4</td><td align="center" valign="middle" >40</td><td align="center" valign="middle" >15</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >阴道切缘</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.881</td><td align="center" valign="middle" >0.17</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >108</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >69</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >SCCA (ng/ml)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >12.23 &#177; 3.80</td><td align="center" valign="middle" >7.10 &#177; 1.43</td><td align="center" valign="middle" >1.585</td><td align="center" valign="middle" >0.216</td></tr><tr><td align="center" valign="middle" >PNI</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >50.11 &#177; 1.09</td><td align="center" valign="middle" >53.23 &#177; 0.64</td><td align="center" valign="middle" >2.484</td><td align="center" valign="middle" >0.012</td></tr></tbody></table></table-wrap></table-wrap-group><p>表1. PLNM阳性和阴性组患者的临床病理学特征比较</p></sec><sec id="s7_4"><title>3.4. IB1~IIA2期宫颈癌PLNM影响因素的Logistic分析结果</title><p>Logistic回归分析显示脉管癌栓、间质浸润 &gt; 1/2和PNI是IB1~IIA2期宫颈癌PLNM的有效预测因子(P &lt; 0.10)。FIGO分期、组织病理类型、病理分化程度、肿瘤直径、阴道切缘、宫旁浸润、SCCA在单因素和多因素分析中均无统计学意义(P &gt; 0.10)，如表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Logistic analysis of PLNM influencing factors in stage IB1~IIA2 cervical cance</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >变量</th><th align="center" valign="middle"  colspan="3"  >单因素</th><th align="center" valign="middle"  colspan="4"  >多因素</th></tr></thead><tr><td align="center" valign="middle" >β</td><td align="center" valign="middle" >OR</td><td align="center" valign="middle" >P</td><td align="center" valign="middle" >β</td><td align="center" valign="middle" >OR</td><td align="center" valign="middle" >95% CI</td><td align="center" valign="middle" >P</td></tr><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >−0.002</td><td align="center" valign="middle" >0.998</td><td align="center" valign="middle" >0.955</td><td align="center" valign="middle" >−0.002</td><td align="center" valign="middle" >0.998</td><td align="center" valign="middle" >0.930~1.071</td><td align="center" valign="middle" >0.957</td></tr><tr><td align="center" valign="middle" >分期</td><td align="center" valign="middle" >0.838</td><td align="center" valign="middle" >2.311</td><td align="center" valign="middle" >0.213</td><td align="center" valign="middle" >0.953</td><td align="center" valign="middle" >2.594</td><td align="center" valign="middle" >0.641~10.498</td><td align="center" valign="middle" >0.182</td></tr><tr><td align="center" valign="middle" >病理</td><td align="center" valign="middle" >0.421</td><td align="center" valign="middle" >1.523</td><td align="center" valign="middle" >0.614</td><td align="center" valign="middle" >0.756</td><td align="center" valign="middle" >2.129</td><td align="center" valign="middle" >0.353~12.834</td><td align="center" valign="middle" >0.410</td></tr><tr><td align="center" valign="middle" >分化</td><td align="center" valign="middle" >1.078</td><td align="center" valign="middle" >2.939</td><td align="center" valign="middle" >0.322</td><td align="center" valign="middle" >1.262</td><td align="center" valign="middle" >3.533</td><td align="center" valign="middle" >0.364~34.257</td><td align="center" valign="middle" >0.276</td></tr><tr><td align="center" valign="middle" >阴道</td><td align="center" valign="middle" >−0.175</td><td align="center" valign="middle" >0.839</td><td align="center" valign="middle" >0.770</td><td align="center" valign="middle" >−21.344</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >直径</td><td align="center" valign="middle" >−0.508</td><td align="center" valign="middle" >0.602</td><td align="center" valign="middle" >0.729</td><td align="center" valign="middle" >−0.404</td><td align="center" valign="middle" >0.668</td><td align="center" valign="middle" >0.188~2.376</td><td align="center" valign="middle" >0.533</td></tr><tr><td align="center" valign="middle" >宫旁</td><td align="center" valign="middle" >0.753</td><td align="center" valign="middle" >2.122</td><td align="center" valign="middle" >0.370</td><td align="center" valign="middle" >1.387</td><td align="center" valign="middle" >4.003</td><td align="center" valign="middle" >0.565~28.367</td><td align="center" valign="middle" >0.165</td></tr><tr><td align="center" valign="middle" >脉管癌栓</td><td align="center" valign="middle" >−2.817</td><td align="center" valign="middle" >0.060</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−2.700</td><td align="center" valign="middle" >0.067</td><td align="center" valign="middle" >0.017~0.264</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >间质浸润</td><td align="center" valign="middle" >−1.814</td><td align="center" valign="middle" >0.163</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >−1.907</td><td align="center" valign="middle" >0.148</td><td align="center" valign="middle" >0.039~0.566</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >SCC</td><td align="center" valign="middle" >−0.019</td><td align="center" valign="middle" >0.981</td><td align="center" valign="middle" >0.176</td><td align="center" valign="middle" >0.010</td><td align="center" valign="middle" >1.010</td><td align="center" valign="middle" >0.971~1.051</td><td align="center" valign="middle" >0.610</td></tr><tr><td align="center" valign="middle" >PNI</td><td align="center" valign="middle" >0.093</td><td align="center" valign="middle" >1.098</td><td align="center" valign="middle" >0.026</td><td align="center" valign="middle" >0.106</td><td align="center" valign="middle" >1.111</td><td align="center" valign="middle" >0.985~1.254</td><td align="center" valign="middle" >0.087</td></tr></tbody></table></table-wrap><p>表2. IB1~IIA2期宫颈癌PLNM影响因素的logistic分析结果</p></sec></sec><sec id="s8"><title>4. 讨论</title><sec id="s8_1"><title>4.1. PNI预测宫颈癌PLNM的价值</title><p>有研究证实，PLNM与宫颈癌的预后有关 [<xref ref-type="bibr" rid="hanspub.39449-ref11">11</xref>]，而PNI可用于预测某些恶性肿瘤淋巴结转移情况 [<xref ref-type="bibr" rid="hanspub.39449-ref12">12</xref>]。到目前为止，PNI与宫颈癌PLNM的关系尚不明了。本研究ROC曲线提示，PNI取值52.2时，曲线下面积最大，为0.752，此时敏感度为69.4%，特异度为74.4%。故将评估IB1~IIA2期宫颈癌PLNM的最佳临界值设定为52.2。本研究单因素、多因素Logistic回归分析均提示，PNI与IB1~IIA2期宫颈癌PLNM显著相关(β = 0.03，OR = 1.098，95% CI为0.985~1.254)。提示PNI &gt; 52.2时，PLNM阴性可能性大，肿瘤增殖、侵袭、转移发生率较低，死亡率较低；PNI ≤ 52.2时，PLNM阳性可能性大，肿瘤增殖、侵袭、转移发生率较高，死亡率较高。本研究证实，脉管癌栓、间质浸润深度、PNI与IB1~IIA2期宫颈癌PLNM有关(P &lt; 0.10)。但运用于术前预测宫颈癌PLNM，相比PNI，宫旁浸润的确定需≥2名主任医师及MRI或CT等辅助检查共同确定，操作相对复杂；而脉管癌栓则需术后组织病理学最终确诊。</p></sec><sec id="s8_2"><title>4.2. PNI预测宫颈癌PLNM的可能机制</title><p>既往研究发现，血清白蛋白下降可致机体合成所需的各种酶减少，酶活性降低，机体免疫力下降，感染机会增加，加强炎症反应。故白蛋白减少是营养不良和免疫防御系统较弱的指标，低蛋白血症提示预后不良 [<xref ref-type="bibr" rid="hanspub.39449-ref12">12</xref>]。淋巴细胞计数可反应患者机体抗肿瘤细胞免疫应答反应作用，血清白蛋白水平和淋巴细胞计数的PNI与恶性肿瘤预后有关 [<xref ref-type="bibr" rid="hanspub.39449-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.39449-ref13">13</xref>] [<xref ref-type="bibr" rid="hanspub.39449-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.39449-ref15">15</xref>]。PNI由外周血中血清白蛋白水平和淋巴细胞计数确定，预测宫颈癌PLNM的机制可能与反映了宫颈癌患者的PLNM与机体抗肿瘤细胞免疫应答反应作用及营养状态的平衡有关：低水平PNI提示机体抗肿瘤细胞免疫应答反应作用与营养状态较差，宫颈癌恶性转化、侵袭和转移可能性较大，PLNM 可能性较大，术中需行子宫颈根治性手术治疗，术后生存率相对较差；高水平PNI往往提示机体抗肿瘤细胞免疫应答反应作用与营养状态较好，宫颈癌恶性转化、侵袭和转移可能性较小，PLNM可能性较小，术中可不行盆腔淋巴结切除术，术后生存率及生活质量相对较好。PNI具有廉价、方便获取、计算简单、实用、有效等优点；纳入了较多可能有影响的变量，结果具有可信性；样本量较多，减少了误差；采血时间间隔短，排除了可能的治疗或药物对结果的干扰。但本研究尚有以下不足：患者术前诊断需由宫颈活检确诊，而后者可能对全身免疫状态有影响；本研究为回顾性、单中心研究，不能排除选择偏倚，各地选择的炎性指标及术前检测项目可能不同，不是所有的血液炎症标记物纳入本研究中；本研究入选病例数较少，FIGO分期、组织病理学类型、病理分化程度、肿瘤直径、阴道切缘阳性、宫旁浸润在单因素及多因素分析中均无统计学意义，而以上指标对宫颈癌的预后与治疗方式选择均有较大影响，需要在今后进行更加深入的研究。综上所述，PNI可作为预测IB1~IIA2期宫颈癌PLNM的独立预测指标，可为该期患者是否行淋巴结清扫提供参考数据，但仍需更多前瞻性、多中心、对照试验证实以上结论。而且，关于PNI的精确取值范围以及其动态变化与宫颈癌PLNM之间的具体联系及机制尚未明确，需要今后进行更加深入的研究论证。</p></sec></sec><sec id="s9"><title>声明</title><p>此研究已获得患者知情同意。</p></sec><sec id="s10"><title>文章引用</title><p>季雪超,陈爱平,王 畅,卢彩霞,赵 飞. 术前PNI与IB1~IIA2期宫颈癌临床病理特征及PLNM的意义Significance of Preoperative PNI in Clinicopathological Characteristics and PLNM of Stage IB1~IIA2 Cervical Cancer[J]. 临床医学进展, 2020, 10(12): 3194-3200. https://doi.org/10.12677/ACM.2020.1012478</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39449-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Mph, R.L.S., et al. (2016) Cancer Statistics, 2016. CA: A Cancer Journal for Clinicians, 66, 7-30.  
https://doi.org/10.3322/caac.21332</mixed-citation></ref><ref id="hanspub.39449-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.39449-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Cohen, P.A., et al. (2019) Cervical Cancer. The Lancet, 393, 169-182.  
https://doi.org/10.1016/S0140-6736(18)32470-X</mixed-citation></ref><ref id="hanspub.39449-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Salvo, G., et al. (2017) Sensitivity and Negative Predictive Value for Sentinel Lymph Node Biopsy in Women with Early-Stage Cervical Cancer. Gynecologic Oncology, 145, 96-101. https://doi.org/10.1016/j.ygyno.2017.02.005</mixed-citation></ref><ref id="hanspub.39449-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Balaya, V., et al. (2019) Predictive Factors of Severe Perioperative Morbidity of Radical Hysterectomy with Lymphadenectomy in Early-Stage Cervical Cancer: A French Prospective Multicentric Cohort of 248 Patients. European Journal of Surgical Oncology, 45, 650-658. https://doi.org/10.1016/j.ejso.2018.10.057</mixed-citation></ref><ref id="hanspub.39449-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Bhatla, N., et al. (2018) Cancer of the Cervix Uteri. International Journal of Gynecology &amp; Obstetrics, 143, 22-36.  
https://doi.org/10.1002/ijgo.12611</mixed-citation></ref><ref id="hanspub.39449-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Mohri, Y., et al. (2013) Prognostic Nutritional Index Predicts Postoperative Outcome in Colorectal Cancer. World Journal of Surgery, 37, 2688-2692. https://doi.org/10.1007/s00268-013-2156-9</mixed-citation></ref><ref id="hanspub.39449-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Miao, Y., et al. (2016) Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy. Oncology Research and Treatment, 39, 712-719.  
https://doi.org/10.1159/000452263</mixed-citation></ref><ref id="hanspub.39449-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Park, S.H., et al. (2020) Prognostic Significance of Body Mass Index and Prognostic Nutritional Index in Stage II/III Gastric Cancer. European Journal of Surgical Oncology, 46, 620-625. https://doi.org/10.1016/j.ejso.2019.10.024</mixed-citation></ref><ref id="hanspub.39449-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Onodera, T., et al. (1984) Prognostic Nutritional Index in Gastrointestinal Surgery of Malnourished Cancer Patients. Nihon Geka Gakkai Zasshi, 85, 1001-1005.</mixed-citation></ref><ref id="hanspub.39449-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Nanthamongkolkul, K. and Hanprasertpong, J. (2018) Predictive Factors of Pelvic Lymph Node Metastasis in Early-Stage Cervical Cancer. Oncology Research and Treatment, 41, 194-198. https://doi.org/10.1159/000485840</mixed-citation></ref><ref id="hanspub.39449-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Armin, S., et al. (2020) Prognostic Nutritional Index (PNI), Independent of Frailty Is Associated with Six-Month Postoperative Mortality. Journal of Geriatric Oncology, 11, 880-884. https://doi.org/10.1016/j.jgo.2020.03.013</mixed-citation></ref><ref id="hanspub.39449-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Kazuhiro, M., et al. (2013) The Prognostic Nutritional Index Predicts Long-Term Outcomes of Gastric Cancer Patients Independent of Tumor Stage. Annals of Surgical Oncology, 20, 2647-2654. https://doi.org/10.1245/s10434-013-2926-5</mixed-citation></ref><ref id="hanspub.39449-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Nozoe, T., et al. (2002) Correlation of Pre-Operative Nutritional Condition with Post-Operative Complications in Surgical Treatment for Oesophageal Carcinoma. European Journal of Surgical Oncology, 28, 396-400.  
https://doi.org/10.1053/ejso.2002.1257</mixed-citation></ref><ref id="hanspub.39449-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Youn, L.J., et al. (2016) Clinical Significance of the Prognostic Nutritional Index for Predicting Short- and Long-Term Surgical Outcomes after Gastrectomy: A Retrospective Analysis of 7781 Gastric Cancer Patients. Medicine, 95, e3539.  
https://doi.org/10.1097/MD.0000000000003539</mixed-citation></ref></ref-list></back></article>